Jon W. G.
- Country
- Denmark
- Department
- Department of Nephrology
Research Overview
- A Randomized, Double-Blind, Placebo-Controlled Study of Resomelagon in Patients with Idiopathic Membranous Nephropathy and Severe Proteinuria
- Long-term Safety and Tolerability Evaluation of Open-label Iptacopan in Adult Patients with Primary IgA Nephropathy: A Rollover Extension Program
- Evaluation of Long-term Safety and Efficacy of Avacopan in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Data & Insights
Has run more than one trial at 25 of 108 partner sites.
Specializations
Glomerular Diseases
This investigator specializes in treating various forms of glomerulonephritis, with particular focus on IgA nephropathy and membranous nephropathy. Their research encompasses innovative therapeutic approaches for patients with severe proteinuria.
- IgA Nephropathy Management
- Membranous Nephropathy Treatment
- Proteinuria Control
The investigator explores novel therapeutic agents for managing chronic glomerular conditions.
Acute Kidney Conditions
Expertise extends to the treatment of acute interstitial nephritis and rapidly progressive glomerulonephritis, investigating both established and experimental therapeutic approaches.
- Interstitial Nephritis Treatment
- RPGN Management
- Steroid Therapy Applications
Their work includes evaluating various treatment modalities for acute kidney conditions.
Therapeutic Innovation
The investigator studies advanced treatments including complement inhibitors and novel therapeutic compounds in nephrology. Their research encompasses both established medications and experimental therapies.
- Novel Drug Development
- Long-term Treatment Outcomes
- Combined Therapy Approaches
Focus includes evaluation of new therapeutic agents for various renal conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.